Larson Financial Group LLC Purchases 1,128 Shares of Cencora, Inc. (NYSE:COR)

Larson Financial Group LLC lifted its position in Cencora, Inc. (NYSE:COR) by 146.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,900 shares of the company’s stock after acquiring an additional 1,128 shares during the quarter. Larson Financial Group LLC’s holdings in Cencora were worth $428,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. New Millennium Group LLC bought a new stake in Cencora in the second quarter worth about $26,000. MFA Wealth Advisors LLC purchased a new stake in shares of Cencora in the second quarter worth approximately $30,000. Concord Wealth Partners bought a new stake in shares of Cencora during the 3rd quarter worth approximately $30,000. LRI Investments LLC purchased a new position in Cencora during the 1st quarter valued at $31,000. Finally, SYSTM Wealth Solutions LLC purchased a new position in Cencora during the 2nd quarter valued at $36,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Up 1.7 %

Cencora stock opened at $248.40 on Wednesday. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The firm has a market cap of $48.95 billion, a P/E ratio of 33.08, a P/E/G ratio of 1.63 and a beta of 0.44. The business has a fifty day moving average of $233.28 and a two-hundred day moving average of $231.85. Cencora, Inc. has a twelve month low of $195.83 and a twelve month high of $251.56.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be paid a dividend of $0.55 per share. This is a boost from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date is Friday, November 15th. Cencora’s dividend payout ratio is 29.29%.

Analyst Ratings Changes

Several research firms have recently weighed in on COR. JPMorgan Chase & Co. lifted their target price on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Wells Fargo & Company boosted their price objective on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research report on Thursday, August 1st. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Robert W. Baird lifted their price target on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Finally, Evercore ISI increased their price objective on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $271.20.

Insider Activity at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the completion of the sale, the chairman now directly owns 306,752 shares of the company’s stock, valued at approximately $74,283,064.32. This represents a 6.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 93,018 shares of company stock valued at $22,478,942 over the last quarter. 15.80% of the stock is owned by corporate insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.